BR112012022802A2 - uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama - Google Patents

uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama

Info

Publication number
BR112012022802A2
BR112012022802A2 BR112012022802A BR112012022802A BR112012022802A2 BR 112012022802 A2 BR112012022802 A2 BR 112012022802A2 BR 112012022802 A BR112012022802 A BR 112012022802A BR 112012022802 A BR112012022802 A BR 112012022802A BR 112012022802 A2 BR112012022802 A2 BR 112012022802A2
Authority
BR
Brazil
Prior art keywords
breast cancer
patient
erbb3 inhibitor
erbb3
cell growth
Prior art date
Application number
BR112012022802A
Other languages
English (en)
Portuguese (pt)
Inventor
Garcia Gabriela
Moyo Victor
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44513103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012022802(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of BR112012022802A2 publication Critical patent/BR112012022802A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112012022802A 2010-03-11 2011-03-11 uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama BR112012022802A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31289510P 2010-03-11 2010-03-11
PCT/US2011/028129 WO2011112953A2 (en) 2010-03-11 2011-03-11 Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers

Publications (1)

Publication Number Publication Date
BR112012022802A2 true BR112012022802A2 (pt) 2018-05-15

Family

ID=44513103

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022802A BR112012022802A2 (pt) 2010-03-11 2011-03-11 uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama

Country Status (20)

Country Link
US (4) US8895001B2 (https=)
EP (2) EP2859893A1 (https=)
JP (2) JP2013522237A (https=)
KR (1) KR101798679B1 (https=)
CN (1) CN102858335B (https=)
AU (1) AU2011224186C1 (https=)
BR (1) BR112012022802A2 (https=)
CA (1) CA2792327C (https=)
DK (1) DK2544680T3 (https=)
EA (1) EA201201186A1 (https=)
ES (1) ES2535503T3 (https=)
IL (1) IL221693A (https=)
MX (1) MX344355B (https=)
NZ (1) NZ602084A (https=)
PL (1) PL2544680T3 (https=)
PT (1) PT2544680E (https=)
SG (1) SG183532A1 (https=)
UA (1) UA111149C2 (https=)
WO (1) WO2011112953A2 (https=)
ZA (1) ZA201206425B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
RS54795B1 (sr) 2009-12-22 2016-10-31 Roche Glycart Ag Anti-her3 antitela i njihova korišćenja
KR101798679B1 (ko) * 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US20140134170A1 (en) * 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
AU2012275850A1 (en) * 2011-06-30 2013-03-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel for treatment of gynecological cancers
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
PH12014500483A1 (en) 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
JP6169085B2 (ja) * 2011-10-06 2017-07-26 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｅｒｂｂ３抗体に対する腫瘍応答の推定
JP2014534965A (ja) 2011-10-13 2014-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コンパニオン診断を用いた乳癌の治療
DK2797957T3 (da) 2011-11-23 2019-09-23 Medimmune Llc Bindingsmolekyler specifikke for her3 og anvendelser deraf
EP3590538A1 (en) * 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
WO2013155346A1 (en) 2012-04-11 2013-10-17 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
EP2912062A1 (en) * 2012-10-24 2015-09-02 Yeda Research and Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
JP2016502974A (ja) * 2012-12-07 2016-02-01 ザ ジェネラル ホスピタル コーポレイション Ｐｉ３ｋ／ａｋｔ阻害剤化合物とｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
JP2018513155A (ja) 2015-04-17 2018-05-24 メリマック ファーマシューティカルズ インコーポレーティッド セリバンツマブを用いた併用療法
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
EP3307326B9 (en) * 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
CN105375955B (zh) * 2015-10-26 2018-07-17 西安电子科技大学 一种信能同传中继网络中的协作传输方法
KR101746152B1 (ko) 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
AU2017235450A1 (en) 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
KR101923641B1 (ko) * 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
US11564987B2 (en) * 2018-10-21 2023-01-31 Slsg Limited Llc Combination immunotherapy for treatment of triple-negative breast cancer
AR117994A1 (es) * 2019-02-05 2021-09-08 Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Métodos para tratar cáncer de mama triple negativo utilizando una proteína mutante de erbb-2 humana
CN112755173B (zh) * 2020-12-31 2022-01-07 深圳市科达顺生物技术有限公司 用于治疗三阴性乳腺癌的Ii-Key/HER2杂交多肽药物及其制备方法
EP4304636A1 (en) * 2021-03-11 2024-01-17 Elevation Oncology, Inc. Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5344760A (en) 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6983227B1 (en) 1995-01-17 2006-01-03 Intertech Ventures, Ltd. Virtual models of complex systems
US5977322A (en) 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
DE69736806T3 (de) 1996-03-27 2015-10-08 Genentech, Inc. ErbB3 ANTIKÖRPER
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
CA2258721C (en) 1996-07-12 2014-09-09 Genentech, Inc. Chimeric heteromultimer adhesins
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US20020002276A1 (en) 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
GB2336695A (en) 1998-04-20 1999-10-27 Teamware Group Oy Modelling a work process
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
KR20110008112A (ko) 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
US7390632B2 (en) 1999-09-30 2008-06-24 Tumor Biology Investment Group, Inc. Soluble ErbB3 receptor isoforms
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20020009740A1 (en) 2000-04-14 2002-01-24 Rima Kaddurah-Daouk Methods for drug discovery, disease treatment, and diagnosis using metabolomics
CA2407556C (en) 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US6871171B1 (en) 2000-10-19 2005-03-22 Optimata Ltd. System and methods for optimized drug delivery and progression of diseased and normal cells
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
AU2002311919B8 (en) * 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
US7612042B2 (en) 2001-05-31 2009-11-03 Tumor Biology Investment Group, Inc. Methods for inhibiting heregulin and treating cancer
US7125680B2 (en) 2001-07-27 2006-10-24 The Regents Of The University Of California Methods and materials for characterizing and modulating interaction between heregulin and HER3
US7662374B2 (en) 2001-08-03 2010-02-16 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbB family members and methods of use thereof
EP1421113A4 (en) 2001-08-03 2005-04-13 Commw Scient Ind Res Org SCREENING BASED ON THE CRYSTAL STRUCTURE OF THE EGF RECEPTOR
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
PL368458A1 (en) 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
US7415359B2 (en) 2001-11-02 2008-08-19 Gene Network Sciences, Inc. Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
AU2003218600C1 (en) 2002-03-26 2009-12-17 Zensun (Shanghai) Science & Technology Co., Ltd. ERBB3 based methods and compositions for treating neoplasms
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
AU2003251597A1 (en) 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
JP4609930B2 (ja) 2002-12-11 2011-01-12 ベンタナ・メディカル・システムズ・インコーポレーテッド Ｈｅｒ−２指向性治療に対する応答を予測する方法
EP1613205B1 (en) 2003-04-01 2013-04-24 Monogram BioSciences, Inc. Erbb surface receptor complexes as biomarkers
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
EP1664716A4 (en) 2003-08-15 2008-08-13 Smithkline Beecham Corp CANCER BIOMARKERS
US8554486B2 (en) 2004-02-20 2013-10-08 The Mathworks, Inc. Method, computer program product, and apparatus for selective memory restoration of a simulation
ES2425749T3 (es) 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
BRPI0510716A (pt) 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
ES2537631T3 (es) 2004-05-27 2015-06-10 The Regents Of The University Of Colorado Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
US7794960B2 (en) 2004-06-04 2010-09-14 Glaxosmithkline Llc Predictive biomarkers in cancer therapy
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
JP2008532476A (ja) 2004-08-12 2008-08-21 ダイアックス コーポレーション 複合結合タンパク質
WO2006044378A2 (en) 2004-10-12 2006-04-27 University Of Iowa Research Foundation Rapid computational identification of targets
WO2006044748A2 (en) 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
WO2006063042A2 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
US7862995B2 (en) 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
CA2599606A1 (en) 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US20060204505A1 (en) 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US20090061422A1 (en) 2005-04-19 2009-03-05 Linke Steven P Diagnostic markers of breast cancer treatment and progression and methods of use thereof
WO2007015935A2 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
WO2007041502A2 (en) 2005-09-30 2007-04-12 Monogram Biosciences Methods for determining responsiveness to cancer therapy
WO2007039705A1 (en) 2005-10-05 2007-04-12 Astrazeneca Uk Limited Method to predict or monitor the response of a patient to an erbb receptor drug
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2007109571A2 (en) 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
EP2049568A2 (en) 2006-04-07 2009-04-22 Københavns Universitet Erbb receptor-derived peptide fragments
US8367351B2 (en) 2006-05-05 2013-02-05 Historx, Inc. Methods for determining signal transduction activity in tumors
JP2009544007A (ja) 2006-07-13 2009-12-10 イェール・ユニバーシティー バイオマーカーの細胞内局在性に基づいて癌予後を行う方法
US20100158894A1 (en) * 2006-09-15 2010-06-24 Tokai University Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same
WO2008073629A2 (en) 2006-11-03 2008-06-19 Board Of Regents, The University Of Texas System Bifunctional predictors of cancer treatment sensitivity and resistance
EP2097754B2 (en) 2006-11-28 2018-01-24 Daiichi Sankyo Europe GmbH Activated her3 as a marker for predicting therapeutic efficacy
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
AU2008239594B2 (en) 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
CA2686908A1 (en) 2007-05-11 2008-11-20 Enzon Pharmaceuticals, Inc. Rna antagonist compounds for the modulation of her3
US20090054051A1 (en) 2007-08-22 2009-02-26 James Cavallo Attachable Headset for Portable Device
MX2010011145A (es) 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
EA201200195A1 (ru) 2009-08-21 2012-12-28 Мерримаск Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
AU2010306774A1 (en) 2009-10-14 2012-05-03 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
WO2011139681A1 (en) 2010-04-26 2011-11-10 Merrimack Pharmaceuticals Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
PH12013500064A1 (en) 2010-07-09 2013-03-11 Exelixis Inc Combinations of kinase inhibitors for the treatment of cancer
FR2963868B1 (fr) 2010-08-11 2012-09-28 Valeo Systemes Thermiques Echangeur de chaleur comprenant un element chauffant serigraphie
EP2648753A4 (en) 2010-12-10 2015-06-24 Merrimack Pharmaceuticals Inc DOSAGE AND ADMINISTRATION OF BISPECIFIC SCFV CONJUGATES
CN103547598A (zh) 2011-02-24 2014-01-29 梅里麦克制药股份有限公司 包含抗-erbb3药剂的联合治疗
US20140134170A1 (en) * 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
MX2013010444A (es) 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
US8476409B2 (en) 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
CN103596592A (zh) 2011-05-06 2014-02-19 梅里麦克制药股份有限公司 用于预防包含抗ErbB3试剂的联合治疗中的毒性药物间相互作用的方法
AU2012273361A1 (en) 2011-06-24 2013-03-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel
AU2012275850A1 (en) 2011-06-30 2013-03-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel for treatment of gynecological cancers
AU2012294326A1 (en) * 2011-08-10 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
MX2014011925A (es) 2012-04-02 2015-05-11 Merrimack Pharmaceuticals Inc Dosificacion y administracion de anticuerpos monoespecíficos y biespecíficos anti- igf 1r y anti erbb3.
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3107578A2 (en) 2014-02-20 2016-12-28 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith

Also Published As

Publication number Publication date
EP2859893A1 (en) 2015-04-15
NZ602084A (en) 2014-07-25
CA2792327A1 (en) 2011-09-15
EA201201186A1 (ru) 2013-11-29
AU2011224186C1 (en) 2015-04-02
SG183532A1 (en) 2012-09-27
MX344355B (es) 2016-12-14
JP2013522237A (ja) 2013-06-13
DK2544680T3 (en) 2015-04-27
PT2544680E (pt) 2015-05-06
AU2011224186A1 (en) 2012-09-13
ZA201206425B (en) 2015-08-26
US20190119401A1 (en) 2019-04-25
US20130034548A1 (en) 2013-02-07
KR20130005280A (ko) 2013-01-15
KR101798679B1 (ko) 2017-11-16
HK1174254A1 (en) 2013-06-07
WO2011112953A2 (en) 2011-09-15
US8895001B2 (en) 2014-11-25
PL2544680T3 (pl) 2015-08-31
UA111149C2 (uk) 2016-04-11
IL221693A (en) 2015-10-29
CN102858335B (zh) 2015-04-15
US20170291957A1 (en) 2017-10-12
ES2535503T3 (es) 2015-05-12
CN102858335A (zh) 2013-01-02
AU2011224186B2 (en) 2014-10-23
CA2792327C (en) 2019-09-24
JP2016166203A (ja) 2016-09-15
MX2012010226A (es) 2013-01-29
EP2544680A2 (en) 2013-01-16
JP6185102B2 (ja) 2017-08-23
US9518130B2 (en) 2016-12-13
EP2544680B1 (en) 2015-01-14
US20150132292A1 (en) 2015-05-14
WO2011112953A3 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
BR112012022802A2 (pt) uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama
MY180365A (en) Markers of tumor cell response to anti-cancer therapy
MX2019014268A (es) Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva.
WO2019067666A8 (en) Therapeutic methods relating to hsp90 inhibitors
CL2015003285A1 (es) Arilquinazolinas
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
ES2422605T3 (es) Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares
BR112015032690A8 (pt) uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases
NZ609201A (en) Means and methods for treating dlbcl
MX372883B (es) Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer.
BR112012031163A2 (pt) métodos de terapia combinada para tratamento de doenças proliferativas
BR112015012295A8 (pt) Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
MX366341B (es) Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer.
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
BR112015033053A2 (pt) método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
BR112016028641A2 (pt) ?método para tratar câncer?
BR112014016723A2 (pt) método para o tratamento de câncer de mama
RU2015152785A (ru) Лечение злокачественной опухоли налтрексоном
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
BR112018011196A2 (pt) uso de pirimido-pirimidazinonas para tratar o câncer
AR082399A1 (es) Receptor de il-18 como un blanco de celulas t reguladoras en cancer
PH12016501554A1 (en) Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2472 DE 22-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.